Safety Monitoring of Medicinal Products: Guidelines for Setting Up and Running a Pharmacovigilance Centre
(2000; 28 pages) [French]
Table of Contents
View the documentINTRODUCTION
View the document1. WHY PHARMACOVIGILANCE?
View the document2. DEFINITION AND AIMS
Open this folder and view contents3. HOW TO START A PHARMACOVIGILANCE CENTRE
Open this folder and view contents4. REPORTING OF ADVERSE DRUG REACTIONS
Open this folder and view contents5. SPECIAL ISSUES IN REPORTING
Open this folder and view contents6. PRACTICALITIES IN THE ORGANISATION OF A PHARMACOVIGILANCE CENTRE
Open this folder and view contents7. ASSESSMENT OF CASE REPORTS
Close this folder8. USE OF THE DATA
View the document8.1 Hypothesis generation and strengthening
View the document8.2 Drug regulation
View the document8.3 Information
View the document8.4 Education and feedback
View the document8.5 Limitations regarding the use of the data
Open this folder and view contents9. RELATIONS WITH OTHER PARTIES
View the document10. OTHER SOURCES OF INFORMATION
View the document11. FUNDING
View the documentREFERENCES
View the documentGLOSSARY
View the documentCAUSALITY CATEGORIES
View the documentWHO CONTACTS
 

8.5 Limitations regarding the use of the data

Usually case reports of suspected adverse reactions may be influenced by all sorts of bias. The interpretation of pharmacovigilance data may be difficult. Often signals are unsubstantiated and require further study for confirmation or refutation (hypothesis testing) and for the assessment of the reaction frequency, for example, as needed for drug regulatory decision-making.

On the one hand a pharmacovigilance centre has the task to stimulate the use of the collected data by healthcare professionals, and on the other hand to ensure that the heterogeneous and largely unproven data are used in a careful and scientifically (and socially) responsible way.

The spontaneous reporting system is especially helpful in the detection of adverse reactions that are specific or occur in a suggestive time-relationship with drug use (e.g. anaphylactic shock), but may be less effective in studying other sorts of adverse reactions (e.g. cancer development). The potential of the spontaneous reporting system to determine the true frequency of adverse reactions is limited.

The detailed reporting of histories of patients with iatrogenic injury and the subsequent use of the reports are to a variable extent subject to rules regarding privacy and medical secrecy. Confidentiality of personal data is needed. The complex of details in a patient history may be as personal as a finger print and therefore a potential identifier. It is advisable for a pharmacovigilance centre to establish data-management protocols, identifying legitimate data-users and describing which data elements are available to whom and for which purpose and which uses are excluded. Confidentiality primarily concerns the secrecy of the identity of all individuals (patient, reporter, doctor) and institutions (hospital) involved. In many countries case report summaries are not considered confidential.

Besides legal obligations, the basis of spontaneous monitoring is the commitment of healthcare practitioners and patients together to make information available. If pharmacovigilance data were used against the wish of reporters, the system as a whole might collapse.

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: December 6, 2017